|
Device | LeukoStrat CDx FLT3 Mutation Assay |
Generic Name | Somatic gene mutation detection system |
Applicant | INVIVOSCRIBE TECHNOLOGIES, INC 10222 Barnes Canyon Road, Building 1 San Diego, CA 92121 |
PMA Number | P160040 |
Date Received | 09/02/2016 |
Decision Date | 04/28/2017 |
Product Code |
OWD |
Docket Number | 17M-2766 |
Notice Date | 05/18/2017 |
Advisory Committee |
Pathology |
Clinical Trials | NCT00651261
|
Expedited Review Granted? | Yes |
Combination Product | No |
Approval Order Statement Approval for the LeukoStrat® CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and the tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStrat® CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom RYDAPT (midostaurin) treatment is being considered. The Leukostrat® CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC, a single site laboratory located at 6330 Nancy Ridge Dr., San Diego, CA 92121. |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S001 S002 S003 S004 S006 S007 S008 S009 S010 S011 S012 S013 |